Literature DB >> 10699717

Desolvation process and surface characteristics of HSA-nanoparticles.

C Weber1, J Kreuter, K Langer.   

Abstract

The objective of the present study was to characterise and optimise the desolvation process of human serum albumin (HSA) for the preparation of nanoparticles. Following the desolvation of the protein, the resulting nanoparticles were stabilised by the addition of varying amounts of glutaraldehyde. The particle size and the number of available amino groups on the surface of the nanoparticles were determined. The results indicated that the particle size depended mainly on the amount of desolvating agent added, but not on the amount of cross-linker. Increasing volumes of glutaraldehyde reduced the number of amino groups on the surface of HSA nanoparticles.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699717     DOI: 10.1016/s0378-5173(99)00420-2

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  31 in total

1.  Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina.

Authors:  Hyuncheol Kim; Shaun B Robinson; Karl G Csaky
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

2.  The Effects of Organic Solvents on the Physicochemical Properties of Human Serum Albumin Nanoparticles.

Authors:  Hossein Mohammad-Beigi; Seyed Abbas Shojaosadati; Dina Morshedi; Negar Mirzazadeh; Ayyoob Arpanaei
Journal:  Iran J Biotechnol       Date:  2016-03       Impact factor: 1.671

3.  Transferrin-coated gadolinium nanoparticles as MRI contrast agent.

Authors:  Huedayi Korkusuz; Karsten Ulbrich; Katerina Welzel; Verena Koeberle; Waralee Watcharin; Ute Bahr; Valery Chernikov; Thomas Knobloch; Sabine Petersen; Frank Huebner; Hanns Ackermann; Svetlana Gelperina; Wolfgang Kromen; Renate Hammerstingl; Joerg Haupenthal; Frank Gruenwald; Jens Fiehler; Stefan Zeuzem; Joerg Kreuter; Thomas J Vogl; Albrecht Piiper
Journal:  Mol Imaging Biol       Date:  2013-04       Impact factor: 3.488

4.  HSA-curcumin nanoparticles: a promising substitution for Curcumin as a Cancer chemoprevention and therapy.

Authors:  Zahra Matloubi; Zuhair Hassan
Journal:  Daru       Date:  2020-04-08       Impact factor: 3.117

5.  Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats.

Authors:  Ji-Eun Chang; Won-Sik Shim; Su-Geun Yang; Eun-Young Kwak; Saeho Chong; Dae-Duk Kim; Suk-Jae Chung; Chang-Koo Shim
Journal:  Pharm Res       Date:  2011-10-05       Impact factor: 4.200

6.  The novel albumin-chitosan core-shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation.

Authors:  Mahdi Karimi; Pinar Avci; Rezvan Mobasseri; Michael R Hamblin; Hossein Naderi-Manesh
Journal:  J Nanopart Res       Date:  2013-04-01       Impact factor: 2.253

7.  Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro.

Authors:  Jin-ming Li; Wei Chen; Hao Wang; Chen Jin; Xian-jun Yu; Wei-yue Lu; Long Cui; De-liang Fu; Quan-xing Ni; Hui-min Hou
Journal:  Acta Pharmacol Sin       Date:  2009-09       Impact factor: 6.150

8.  A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine.

Authors:  Priti Girotra; Shailendra Kumar Singh
Journal:  Pharm Res       Date:  2016-03-22       Impact factor: 4.200

9.  EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.

Authors:  Zixuan Ye; Yue Zhang; Yuanfen Liu; Yanyan Liu; Jiasheng Tu; Yan Shen
Journal:  Int J Nanomedicine       Date:  2021-03-26

10.  Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate-conjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM).

Authors:  Yuangang Zu; Yu Zhang; Xiuhua Zhao; Qi Zhang; Yang Liu; Ru Jiang
Journal:  Int J Nanomedicine       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.